Status: Recruiting
Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer
This is a single-arm, exploratory trial to evaluate the efficacy and safety of neoadjuvant WX-0593 in patients with resectable ALK-positive or ROS1- positive non-small cell lung cancer(NSCLC).
Participants needed: 26
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Pingping SongUpdated: Jun 12, 2025Locations: 1
Eligibility criteria
Histologically confirmed non-small cell lung cancer (NSCLC). [+5]
Prior treatment with any systemic anti-cancer therapy for NSCLC including chemot... [+4]